These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 7473136)

  • 1. Disposition characteristics of recombinant human interleukin-11 after a bolus intravenous administration in mice.
    Takagi A; Masuda H; Takakura Y; Hashida M
    J Pharmacol Exp Ther; 1995 Nov; 275(2):537-43. PubMed ID: 7473136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of recombinant human interleukin 3 administered subcutaneously and by continuous intravenous infusion in patients after chemotherapy for ovarian cancer.
    Biesma B; Pokorny R; Kovarik JM; Duffy FA; Willemse PH; Mulder NH; de Vries EG
    Cancer Res; 1993 Dec; 53(24):5915-9. PubMed ID: 8261403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative tissue distribution of 125I- and U-14C-labeled recombinant human interleukin-2 in the rat.
    Sabo J; Ni G; Nadeau R; Liberato DJ; Loh A
    Lymphokine Cytokine Res; 1992 Aug; 11(4):229-33. PubMed ID: 1420601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal disposition of recombinant human interleukin-11 in the isolated perfused rat kidney.
    Takagi A; Yabe Y; Oka Y; Sawai K; Takakura Y; Hashida M
    Pharm Res; 1997 Jan; 14(1):86-90. PubMed ID: 9034226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and disposition characteristics of recombinant decorin after intravenous injection into mice.
    Masuda H; Takakura Y; Hashida M
    Biochim Biophys Acta; 1999 Feb; 1426(3):420-8. PubMed ID: 10076058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fate and biological action of human recombinant interleukin 1 beta in the rat in vivo.
    Klapproth J; Castell J; Geiger T; Andus T; Heinrich PC
    Eur J Immunol; 1989 Aug; 19(8):1485-90. PubMed ID: 2476319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
    Atkins MB; Robertson MJ; Gordon M; Lotze MT; DeCoste M; DuBois JS; Ritz J; Sandler AB; Edington HD; Garzone PD; Mier JW; Canning CM; Battiato L; Tahara H; Sherman ML
    Clin Cancer Res; 1997 Mar; 3(3):409-17. PubMed ID: 9815699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clearance of recombinant tissue factor pathway inhibitor (TFPI) in rabbits.
    Palmier MO; Hall LJ; Reisch CM; Baldwin MK; Wilson AG; Wun TC
    Thromb Haemost; 1992 Jul; 68(1):33-6. PubMed ID: 1514170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of 111In-labeled anti-p97 monoclonal antibody in patients with metastatic malignant melanoma.
    Rosenblum MG; Murray JL; Haynie TP; Glenn HJ; Jahns MF; Benjamin RS; Frincke JM; Carlo DJ; Hersh EM
    Cancer Res; 1985 May; 45(5):2382-6. PubMed ID: 3986780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and tissue distribution of recombinant human tumor necrosis factor-alpha in mice.
    Ferraiolo BL; Moore JA; Crase D; Gribling P; Wilking H; Baughman RA
    Drug Metab Dispos; 1988; 16(2):270-5. PubMed ID: 2898346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted delivery of human recombinant superoxide dismutase by chemical modification with mono- and polysaccharide derivatives.
    Fujita T; Nishikawa M; Tamaki C; Takakura Y; Hashida M; Sezaki H
    J Pharmacol Exp Ther; 1992 Dec; 263(3):971-8. PubMed ID: 1469654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant human parathyroid hormone 1-34: pharmacokinetics, tissue distribution and excretion in rats.
    Hu Z; Niu H; Yang X; Li H; Sang G; Li B
    Int J Pharm; 2006 Jul; 317(2):144-54. PubMed ID: 16621369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of mass balance, pharmacokinetics and disposition of [14C(U)]- and [125I]recombinant human interleukin-2 in cynomolgus monkeys.
    Nadeau RW; Satoh H; Scheide S; Crowl R; Conroy R; Garland WA; Liberato DJ
    Drug Metab Dispos; 1995 Sep; 23(9):904-9. PubMed ID: 8565779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uptake of indium-111-labeled platelets and indium-111 oxine by murine kidneys after total-body irradiation.
    Ebbe S; Taylor S; Maurer H; Kullgren B
    Radiat Res; 1996 Aug; 146(2):216-22. PubMed ID: 8693071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic disposition characteristics of recombinant human interleukin-11 (rhIL-11) in the perfused rat liver.
    Takagi A; Yabe Y; Yoshida M; Takakura Y; Hashida M
    Biol Pharm Bull; 1998 Dec; 21(12):1364-6. PubMed ID: 9881656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of [125I]-recombinant human interleukin-11: 1. Absorption, distribution and excretion after subcutaneous administration to male rats.
    Uchida T; Aoyama K; Mori K; Usui T; Watanabe T; Takariki Y; Asahara N; Hirose M; Kimura T; Tateishi M; Higuchi S
    Eur J Drug Metab Pharmacokinet; 1998; 23(3):403-10. PubMed ID: 9842984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of human activated protein C. 2nd communication: tissue distribution study of a lyophilized purified human activated protein C after single or repeated intravenous administration in male mice and placental transfer and milk passage study after intravenous administration in pregnant and lactating mice.
    Ishii S; Mochizuki T; Nagao T; Kudo S; Fujita A; Taniguchi K; Kondo S; Kiyoki M
    Arzneimittelforschung; 1995 May; 45(5):644-56. PubMed ID: 7612069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of human activated protein C. 1st communication: plasma concentration and excretion of a lyophilized purified human activated protein C after intravenous administration in the mouse and the rabbit.
    Ishii S; Mochizuki T; Nagao T; Sugiki S; Kudo S; Harakawa N; Taniguchi K; Igarashi Y; Kondo S; Kiyoki M
    Arzneimittelforschung; 1995 May; 45(5):636-44. PubMed ID: 7612068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of co-administration of cationic macromolecules on the in vivo disposition and in situ renal disposition characteristics of rhIL-11.
    Takagi A; Yabe Y; Oka Y; Takakura Y; Hashida M
    Drug Metab Pharmacokinet; 2002; 17(2):136-41. PubMed ID: 15618662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of recombinant human interleukin-11 (rhIL-11) in healthy male subjects.
    Aoyama K; Uchida T; Takanuki F; Usui T; Watanabe T; Higuchi S; Toyoki T; Mizoguchi H
    Br J Clin Pharmacol; 1997 Jun; 43(6):571-8. PubMed ID: 9205816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.